Buscas alternativas:
"eoto open" » "oto open" (Expandir a Busca), "motor open" (Expandir a Busca), "rotor open" (Expandir a Busca), "eotdo open" (Expandir a Busca), "eotao open" (Expandir a Busca), "eoto opens" (Expandir a Busca)
"caso open" » "case open" (Expandir a Busca), "caso lopez" (Expandir a Busca), "cases open" (Expandir a Busca), "casdo open" (Expandir a Busca), "casao open" (Expandir a Busca), "caso opens" (Expandir a Busca)
"esmo open" » "esmdo open" (Expandir a Busca), "esmao open" (Expandir a Busca), "esmo opens" (Expandir a Busca), "esto open" (Expandir a Busca), "eso open" (Expandir a Busca), "ecmo open" (Expandir a Busca)
"o open" » "do open" (Expandir a Busca), "ao open" (Expandir a Busca), "o opens" (Expandir a Busca)
Mostrando 1 - 20 resultados de 962 para a busca '(((((("eoto open") OR ("caso open"))) OR ("esmo open"))) OR ("o open"))', tempo de busca: 1.28s Refinar Resultados
AIOM chooses ESMO Open—Cancer Horizons as its official journal: a warm welcome from ESMO Open
ESMO Open—Cancer Horizons and the future of oncology

CSCO joins ESMO Open—Cancer Horizons
ESMO Open: news in breast cancer 2019

ESMO Open welcomes the association with the Japanese Society of Medical Oncology (JSMO)
ESMO Open special series on new emerging targets in cancer immunotherapy

Announcing the ESMO Open special issue on upcoming molecular targets for cancer treatment
One year of ESMO Open: Cancer Horizons—where are we going from here?

Introducing a new ESMO Open article series: how I treat side effects of immunotherapy
Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open–Cancer Horizons roundtable discussion

First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion
CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Open—Cancer Horizons pro and con discussion

EDUCAÇÃO A DISTÂNCIA: O CASO OPEN UNIVERSITY
New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an “ESMO Open – Cancer Horizons” Series

Erratum to ‘FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out?’: [ESMO Open Volume 5, Issue 5, 2020, e000633]
Erratum to ‘Adjuvant endocrine therapy in HER2-positive breast cancer patients: systematic review and meta-analysis’: [ESMO Open Volume 6, Issue 2, April 2021, 100088]

Corrigendum to ‘Clinical significance of ERBB2 exon 16 skipping: analysis of a real-world retrospective observational cohort study’: [ESMO Open Volume 5, Issue 6, 2020, e000985]
Erratum to ‘Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome’: [ESMO Open Volume 6, Issue 1, February 2021, 100005]

A lei geral de proteção de dados e o open finance
Corrigendum to ‘The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer’: [ESMO Open Volume 6, Issue 2, April 2021, 100078]

Ferramentas de busca: Obter Feed RSS — Enviar busca por e-mail — Salvar a busca